Back

Effects of Dapagliflozin on myocardial performance in non-diabetic patients with Heart failure with reduced and mid-range ejection fraction (DAPA ECHO trial)

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Phenotypic approach in heart failure therapy Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speakers

Photo
Doctor Maria Concetta Pastore

University of Siena, Siena (Italy)

Photo
Doctor Andrea Stefanini

University of Siena, Siena (Italy)

7 More presentations in this session

Presentation thumbnail
In-hospital initiation of Vericiguat and short-term cardiovascular function improvement in heart failure patients with worsened renal function
Professor J. She (Xi'an, CN)
Abstract Slides Video
Presentation thumbnail
Comparison of ventricular tachyarrhythmias in HF patients on dapagliflozin versus empagliflozin
Doctor P. Wilson (Dallas, US)
Abstract Slides Video
Presentation thumbnail
Intermittent levosimendan infusions for advanced heart failure: a systematic review and meta-analysis of randomized controlled trials.
Doctor M. Abouzid (Poznan, PL)
Abstract Slides Video
Presentation thumbnail
Real-world eligibility for GLP1-ra therapy in a cohort of heart failure patients
Doctor A. Villaschi (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Secondary erythrocytosis / polycythemia due to sodium glucose co-transporter 2 inhibitors: a real world heart failure cohort.
Miss M. Pherai (Rotterdam, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Phenotypic approach in heart failure therapy

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Deformation Imaging by Strain in Chronic heart failure Over gliflozins: an Echocardiographic Register on Sodium-GLucose coTransporter-2 inhibitors (DISCOVER SGLT2i)
thumbnail
Congress Presentation
Characteristics of patients initiating dapagliflozin for heart failure with reduced ejection fraction in Italian clinical practice: a 6-month interim analysis of EVOLUTION-HF Italy
thumbnail
Congress Presentation
Dapagliflozin effect on cardiopulmonary function, reverse cardiac remodelling and biomarkers in a cohort of HFrEF patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources